|View printer-friendly version|
Company Will Advance Three Clinical Stage Product Candidates Addressing Significant Unmet Needs in Dry-AMD, Spinal Cord Injury, and Immuno-Oncology
“This acquisition is a key step in our plan to turn
- OpRegen® - a retinal pigment epithelium cell replacement therapy currently being tested in a Phase I/IIa multicenter clinical trial for the treatment of advanced dry-age-related macular degeneration (dry-AMD) with geographic atrophy. OpRegen® has been granted Fast Track designation from the
U.S. Food and Drug Administration( FDA).
- OPC1 - an oligodendrocyte progenitor cell therapy currently being tested in a Phase I/IIa multicenter clinical trial (the “SciStar Study”) for the treatment of acute spinal cord injuries (SCI). The clinical development of OPC1 has been partially funded by a
$14.3 milliongrant from the California Institute for Regenerative Medicine. OPC1 has received Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of acute SCI and has been granted Orphan Drug Designation by the FDA.
- VAC2 - an allogeneic (non-patient-specific or “off-the-shelf”) cancer immunotherapy of antigen-presenting dendritic cells currently being tested in a Phase I clinical trial in non-small cell lung cancer (NSCLC) fully funded and conducted by
Cancer Research UK, the world’s largest independent cancer research charity.
Following the closing of the merger,
BioTime’s financial advisor in the transaction was
Certain statements contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of
BioTime Inc. IR
Ioana C. Hone
Solebury Trout IR
Gitanjali Jain Ogawa